Cargando…
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
SIMPLE SUMMARY: Bruton tyrosine kinase (Btk) is expressed in B-lymphocytes, myeloid cells and platelets. Since the launch of the first in class Btk-inhibitor (BTKi) ibrutinib in 2013, the list of indications and further drug candidates has expanded greatly. BTKi are not only used to treat patients w...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961939/ https://www.ncbi.nlm.nih.gov/pubmed/33806595 http://dx.doi.org/10.3390/cancers13051103 |